COVID-19 press releases

COVID-19 press releases

After assessing safety and immunogenicity in phase 1/2 clinical trials, NVX-CoV2373 is currently in two pivotal phase 3 studies to evaluate vaccine efficacy, safety and immunogenicity. 

NVX-CoV2373 clinical trials have enrolled more than 30,000 volunteers around the globe. Learn more about our clinical trial enrollment and progress toward diversity demographics.

Nov 29, 2022
COVID-19

World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults

Nov 23, 2022
Statement
COVID-19

Termination of COVID-19 Vaccine Purchase Agreement with Gavi

Nov 18, 2022
COVID-19

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Nov 9, 2022
COVID-19

Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults

Nov 8, 2022
COVID-19

Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster

Oct 20, 2022
COVID-19,Seasonal influenza

Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022

Oct 19, 2022
Statement
COVID-19

U.S. Centers for Disease Control and Prevention Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults

Oct 19, 2022
COVID-19

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults

Oct 13, 2022
COVID-19,Seasonal influenza

Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains

Oct 12, 2022
COVID-19

Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants

Highlights

Visit our global authorization website

Our commitment to equitable access and transparency

Announcement of UK and South Africa trial results

Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial

PREVENT-19 fact sheet

Background information on PREVENT-19, Novavax pivotal phase 3 trial

Showper page